PCI Biotech Holding ASA (OSL:PCIB) 5-Year Share Buyback Ratio : 0.00% (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA 5-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. PCI Biotech Holding ASA's current 5-Year Share Buyback Ratio was 0.00%.

OSL:PCIB's 5-Year Share Buyback Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: -10.2
* Ranked among companies with meaningful 5-Year Share Buyback Ratio only.

Competitive Comparison of PCI Biotech Holding ASA's 5-Year Share Buyback Ratio

For the Biotechnology subindustry, PCI Biotech Holding ASA's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's 5-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's 5-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's 5-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

PCI Biotech Holding ASA 5-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

PCI Biotech Holding ASA (OSL:PCIB) 5-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

PCI Biotech Holding ASA 5-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's 5-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » 5-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

0JGL:UK

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines